Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact

Executive Summary

In theory, reviewing generic applications faster should speed competition; in practice, FDA's new policy likely won't make too much difference.


Related Content

Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
Generic Drug Market Has Gaps, FDA Tells Firms In Solicitation For ANDAs
FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit
FDA Aims To 'Pierce The Rhetoric' On Generic Application Backlog
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
EpiPen Generics: Woodcock Explains Injector Studies
GDUFA II Will Include Small Business Relief, Priority ANDA Reviews
EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review
Why Generic EpiPen Is Not The Answer – Until FDA Says It Is
FDA’s Priority Reviews May Have Helped Reduce New Drug Shortages


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts